Table 2 ELPs as nanocarriers discussed in this review

M-ELP_90A,120 M-ELP_90A,80

Passive diffusion

28.8 ~ 60.4

2.34 ± 0.50

Doxorubicin paclitaxel

22.7 ± 0.6

Exhibit cytotoxic effects on cancer cells,

Prolong blood circulation time.

[26]

FKBP12-ELP-RGD

Affinity between FKBP12/Rapa

25.0

Dapamycin (Rapa)

22.7 ± 0.2

Inhibit the mTOR signaling pathway,

Reduce hemolytic side effects, hepatotoxicity and nephrotoxicity of the drug.

[112]

Cyclophilin A (CypA)-ELP(A192)

Affinity between CypA/CsA

49.3

957.3 

Cyclosporine A (CsA)

a.7.4 ± 0.7

b. 113.0 ± 59.1

Prolong the drug half-life,

Increase the mean residence time,

Reduce renal drug toxicity.

[113]

ELP(E)₁₂₀

Cysteine disulfide coupling

18.2

Paclitaxel

R_h:58 ± 0.2

R_g:49 ± 0.1

Prolong drug cycle time,

A single dose of treatment almost completely eradicated the tumor.

[114]

F-TRAP

ELP

C-terminal binding domain attachment of F-TRAP

35

Fluorine-19 (¹⁹ F)

30.3 ± 0.6

 F-TRAP signal can be detected within 7 min,

Effective treatment of MCF-7 breast adenocarcinoma cells.

[115]